Pages that link to "Q36702208"
Jump to navigation
Jump to search
The following pages link to Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear (Q36702208):
Displaying 50 items.
- New Therapeutic Approaches in Polycythemia Vera (Q26795677) (← links)
- Advances in the management of myelofibrosis (Q27008072) (← links)
- The adaptor Lnk (SH2B3): An emerging regulator in vascular cells and a link between immune and inflammatory signaling (Q28242194) (← links)
- Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis (Q33400683) (← links)
- Immunomodulatory agents in myelofibrosis (Q33401615) (← links)
- Emerging drugs for myelofibrosis (Q33404574) (← links)
- Ruxolitinib: a new treatment option for myelofibrosis (Q33405241) (← links)
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial (Q33421596) (← links)
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial (Q33432637) (← links)
- Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis (Q33433006) (← links)
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis (Q33434284) (← links)
- Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202 (Q33436442) (← links)
- Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase (Q33558154) (← links)
- F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Appearance of Extramedullary Hematopoesis in a Case of Primary Myelofibrosis (Q33711600) (← links)
- Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. (Q33952753) (← links)
- Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients (Q34419687) (← links)
- Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 cases (Q34474214) (← links)
- JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis (Q34652224) (← links)
- Choosing between stem cell therapy and drugs in myelofibrosis (Q34734491) (← links)
- Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. (Q34750599) (← links)
- Characterising neovascularisation in fracture healing with laser Doppler and micro-CT scanning (Q34861945) (← links)
- Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms (Q35433425) (← links)
- Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis (Q35677969) (← links)
- Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications (Q36116382) (← links)
- Myeloproliferative Neoplasms in Children (Q36305041) (← links)
- The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course (Q36788138) (← links)
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms (Q36843673) (← links)
- The history of myeloproliferative disorders: before and after Dameshek (Q36946585) (← links)
- Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens (Q37009717) (← links)
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis (Q37034988) (← links)
- Genetic-pathologic characterization of myeloproliferative neoplasms (Q37151437) (← links)
- Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis (Q37163487) (← links)
- Miscreant myeloproliferative disorder stem cells (Q37299267) (← links)
- Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. (Q37310619) (← links)
- Allogeneic hematopoietic cell transplantation for patients with myelofibrosis (Q37495397) (← links)
- Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. (Q37532323) (← links)
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (Q37552023) (← links)
- From leeches to personalized medicine: evolving concepts in the management of polycythemia vera (Q37555790) (← links)
- FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders (Q37675522) (← links)
- Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis (Q37738536) (← links)
- Future Therapies for the Myeloproliferative Neoplasms (Q37809804) (← links)
- Treatment options for essential thrombocythemia and polycythemia vera (Q37810107) (← links)
- Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation (Q37817621) (← links)
- Management of Myelofibrosis (Q37967277) (← links)
- Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work? (Q37968531) (← links)
- BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques (Q38014534) (← links)
- Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature (Q38041128) (← links)
- Myelofibrosis: an update on current pharmacotherapy and future directions (Q38091447) (← links)
- Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis (Q38143243) (← links)
- The new landscape of therapy for myelofibrosis (Q38150261) (← links)